<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168235">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01999699</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-22</org_study_id>
    <nct_id>NCT01999699</nct_id>
  </id_info>
  <brief_title>A Study of the Immune Response to Heplisav in Healthy Older Adults</brief_title>
  <official_title>A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the response of the immune system to a hepatitis B vaccine in
      healthy adults 50 to 70 years of age.  This study is partially funded by the National
      Institute of Allergy and Infectious Diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to examine how the immune system responds to vaccination with
      HEPLISAV.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Evaluate the changes in cellular responses and gene expression patterns in serial blood samples collected from healthy older adults after vaccination with HEPLISAV.</measure>
    <time_frame>Day 1, 3, and 7 and on Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine which of these changes correlate with the development of protective levels of antibody (anti-HBs &gt;/= 10 mIU/mL) to HBV.</measure>
    <time_frame>Day 1, 3, and 7 and on Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HEPLISAV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV</intervention_name>
    <arm_group_label>HEPLISAV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 to 70 years of age, inclusive

          -  In good health in the opinion of the principal investigator, based upon medical
             history and physical examination

          -  Serum negative for HBsAg, anti-HBs, antibody to hepatitis B core antigen (anti-HBc),
             hepatitis C virus (HCV), and human immunodeficiency virus (HIV)

          -  If female of childbearing potential, agree to consistently use a highly effective
             method of birth control from the screening visit through Week 12/Visit 10

        Exclusion Criteria:

          -  Pregnant, breastfeeding, or planning a pregnancy

          -  Known history of an autoimmune disease

          -  Previously received any hepatitis B vaccine (approved or investigational)

          -  Body-mass index (BMI) &gt;30 kg/m2, diabetes mellitus (type 1 or 2), or other chronic
             medical condition that in the opinion of the principal investigator might interfere
             with the immune response to hepatitis B vaccination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Janssen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dynavax Technologies Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johnson County Clinical Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dynavax.com</url>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heplisav</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
